Secondary Prevention

• 

  Subject Areas on Research

  • 17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial. 
  • 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 
  • 2015 ACC/AHA Focused Update of Secondary Prevention Lipid Performance Measures: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. 
  • 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 
  • A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. 
  • A Preliminary Investigation of a Relapse Prevention Mobile Application to Maintain Smoking Abstinence Among Individuals With Posttraumatic Stress Disorder. 
  • A Smart and Multifaceted Mobile Health System for Delivering Evidence-Based Secondary Prevention of Stroke in Rural China: Design, Development, and Feasibility Study. 
  • A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. 
  • A freeze on tailored antiplatelet therapy? 
  • A mathematical model to evaluate the routine use of fecal microbiota transplantation to prevent incident and recurrent Clostridium difficile infection. 
  • A motivational intervention can improve retention in PCIT for low-motivation child welfare clients. 
  • A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. 
  • Achievement of guideline-concordant care and in-hospital outcomes in patients with coronary artery disease in teaching and nonteaching hospitals: results from the Get With The Guidelines-Coronary Artery Disease program. 
  • Acid Suppression Therapy and Symptom Improvement (or Lack Thereof) in Children. 
  • Acute upper airway angioedema secondary to acquired C1 esterase inhibitor deficiency: a case report. 
  • Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocks. 
  • Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis. 
  • Adjuvant therapy after surgical stone management. 
  • Advances in opioid antagonist treatment for opioid addiction. 
  • Advances in stroke: Prevention and health services delivery 2012-2013. 
  • Age and persistent use of cardiovascular medication after acute coronary syndrome: results from medication applied and sustained over time. 
  • Alemtuzumab induction and recurrence of glomerular disease after kidney transplantation. 
  • American Society of Clinical Oncology statement: achieving high-quality cancer survivorship care. 
  • Anticoagulants and antiplatelet agents in acute ischemic stroke: report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a division of the American Heart Association). 
  • Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. 
  • Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. 
  • Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. 
  • Antithrombotic agents for secondary prevention after acute coronary syndromes: A systematic review and network meta-analysis. 
  • Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. 
  • Applying the evidence in coronary disease secondary prevention: a call to action. 
  • Assessing oral beta-blocker therapy after percutaneous coronary intervention for ST-segment elevation myocardial infarction: the role of observational data. 
  • Association between early postoperative nutritional supplement utilisation and length of stay in malnourished hip fracture patients. 
  • Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry. 
  • Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. 
  • Association of a P2Y12 Inhibitor Copayment Reduction Intervention With Persistence and Adherence With Other Secondary Prevention Medications: A Post Hoc Analysis of the ARTEMIS Cluster-Randomized Clinical Trial. 
  • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. 
  • Association of statin therapy with outcomes of acute coronary syndromes: the GRACE study. 
  • Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention. 
  • Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. 
  • Azimilide for the treatment of atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia: results of a randomized trial and insights on the concordance of symptoms and recurrent arrhythmias. 
  • B cell-directed therapies for autoimmune disease and correlates of disease response and relapse. 
  • Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. 
  • Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. 
  • Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. 
  • Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. 
  • Beyond the Window: Patient Characteristics and Geographic Locations Associated with Late Prenatal Care in Women Eligible for 17-P Preterm Birth Prevention. 
  • Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease. 
  • Bipolar arthroplasty for recurrent total hip instability. 
  • Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. 
  • Can involuntary outpatient commitment reduce hospital recidivism?: Findings from a randomized trial with severely mentally ill individuals. 
  • Can my patient dive after a first episode of primary spontaneous pneumothorax? A systematic review of the literature. 
  • Canadian stroke best practice consensus statement: Secondary stroke prevention during pregnancy. 
  • Care of the Pediatric Patient on Chronic Dialysis. 
  • Centers for Medicare and Medicaid Services' Decision to Reconsider Coverage Indications for ICDs: Where to Now? 
  • Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. 
  • China's response to the rising stroke burden. 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. 
  • Chronic kidney disease and stroke. 
  • Chronic myelogenous leukemia. 
  • Clinical risk factors for recurrent fracture after hip fracture: a prospective study. 
  • Clinical trial: interferon alpha-2b continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic hepatitis C. 
  • Cognitive-behavioral therapy for suicide prevention (CBT-SP): treatment model, feasibility, and acceptability. 
  • Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. 
  • Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. 
  • Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). 
  • Complete Revascularization with Multivessel PCI for Myocardial Infarction. 
  • Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. 
  • Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease. 
  • Contemporary approach to the diagnosis and management of non-ST-segment elevation acute coronary syndromes. 
  • Contemporary therapy of acute ST-elevation myocardial infarction. 
  • Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE). 
  • Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. 
  • Coronary intervention for persistent occlusion after myocardial infarction. 
  • Cost-effectiveness of primary versus secondary prophylaxis with pegfilgrastim in women with early-stage breast cancer receiving chemotherapy. 
  • Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. 
  • Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. 
  • Death and rehospitalization after transient ischemic attack or acute ischemic stroke: one-year outcomes from the adherence evaluation of acute ischemic stroke-longitudinal registry. 
  • Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. 
  • Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). 
  • Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. 
  • Designing mental health interventions informed by child development and human biology theory: a social ecology intervention for child soldiers in Nepal. 
  • Development and Local Contextualization of Mobile Health Messages for Enhancing Disease Management Among Community-Dwelling Stroke Patients in Rural China: Multimethod Study. 
  • Development of a mobile phone-based intervention to improve adherence to secondary prevention of coronary heart disease in China. 
  • Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. 
  • Device Closure Versus Medical Therapy Alone for Patent Foramen Ovale in Patients With Cryptogenic Stroke: A Systematic Review and Meta-analysis. 
  • Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. 
  • Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. 
  • Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. 
  • Direct Oral Anticoagulants in Addition to Antiplatelet Therapy for Secondary Prevention After Acute Coronary Syndromes: A Systematic Review and Meta-analysis. 
  • Does silent myocardial infarction add prognostic value in ST-elevation myocardial infarction patients without a history of prior myocardial infarction? Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Trial. 
  • Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. 
  • Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial. 
  • Edoxaban in the secondary prevention of VTE. 
  • Effect of Mobile Health Interventions on the Secondary Prevention of Cardiovascular Disease: Systematic Review and Meta-analysis. 
  • Effect of a Multifaceted Quality Improvement Intervention on Hospital Personnel Adherence to Performance Measures in Patients With Acute Ischemic Stroke in China: A Randomized Clinical Trial. 
  • Effect of medical management on recurrent stone formation following percutaneous nephrolithotomy. 
  • Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. 
  • Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial. 
  • Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. 
  • Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Efficacy and safety of fidaxomicin compared with oral vancomycin for the treatment of adults with Clostridium difficile-associated diarrhea: data from the OPT-80-003 and OPT-80-004 studies. 
  • Efficacy of a Nurse-Delivered Intervention to Prevent and Delay Postpartum Return to Smoking: The Quit for Two Trial. 
  • Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. 
  • Efficacy of multiple intraarterial papaverine infusions for improvement in cerebral circulation time in patients with recurrent cerebral vasospasm. 
  • Elective stoma construction improves outcomes in medically intractable pressure ulcers. 
  • Engaging the Entire Care Cascade in Western Kenya: A Model to Achieve the Cardiovascular Disease Secondary Prevention Roadmap Goals. 
  • Enhancing recovery in coronary heart disease patients (ENRICHD): study design and methods. The ENRICHD investigators. 
  • Eosinophilic granuloma. A different behaviour in children than in adults. 
  • Etanercept plus standard therapy for Wegener's granulomatosis. 
  • Evidence-based urology in practice: P-values vs confidence intervals. 
  • Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. 
  • Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks. 
  • Fibrinolysis for acute myocardial infarction: the future is here and now. 
  • First-line pharmacotherapy approaches for generalized anxiety disorder. 
  • Folic acid supplementation and chronic kidney disease progression. 
  • Foot and Ankle Surgery: Common Problems and Solutions. 
  • Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial. 
  • From the editor: Confronting a pandemic or two. 
  • Future directions in research on psychotherapy for adolescent depression. 
  • Gender differences in outcomes after primary angioplasty versus primary stenting with and without abciximab for acute myocardial infarction: results of the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. 
  • Gene inhibition and gene augmentation for the treatment of vascular proliferative disorders. 
  • Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. 
  • HIV type 1 (HIV-1) proviral reservoirs decay continuously under sustained virologic control in HIV-1-infected children who received early treatment. 
  • Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. 
  • High-dose atorvastatin after stroke or transient ischemic attack. 
  • Hospital Variation in Adherence Rates to Secondary Prevention Medications and the Implications on Quality. 
  • How much can be gained by more systematic prevention of stroke? 
  • Impact of Cardiac Rehabilitation and Exercise Training on Psychological Risk Factors and Subsequent Prognosis in Patients With Cardiovascular Disease. 
  • Impact of Secondary Prevention in an Occupational High-Risk Group. 
  • Implications of prior myocardial infarction for patients presenting with an acute myocardial infarction. 
  • Importance and Challenges of Moving Stroke Prevention into the Community. 
  • In-hospital worsening heart failure. 
  • Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. 
  • Incidence and predictors of microbiology results returning postdischarge and requiring follow-up. 
  • Incorporating primary and secondary prevention approaches to address childhood obesity prevention and treatment in a low-income, ethnically diverse population: study design and demographic data from the Texas Childhood Obesity Research Demonstration (TX CORD) study. 
  • Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. 
  • Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia. 
  • Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. 
  • Insights on the robust variance estimator under recurrent-events model. 
  • Intensity of Lipid Lowering With Statin Therapy in Patients With Cerebrovascular Disease Versus Coronary Artery Disease: Insights from the PALM Registry. 
  • International consensus statement on major depressive disorder. 
  • Interventions for suicidal youth: a review of the literature and developmental considerations. 
  • Intravascular radiation therapy after balloon angioplasty of narrowed femoropopliteal arteries to prevent restenosis: results of the PARIS feasibility clinical trial. 
  • Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. 
  • Intravitreal bevacizumab for macular edema due to central retinal vein occlusion: perfused vs. ischemic and early vs. late treatment. 
  • Investigational drugs in phase II clinical trials for acute coronary syndromes. 
  • Is there a definition of remission in late-life depression that predicts later relapse? 
  • Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. 
  • Kinetics of hepatitis C virus reinfection after liver transplantation. 
  • Left ventricular ejection fraction assessment among patients with acute myocardial infarction and its association with hospital quality of care and evidence-based therapy use. 
  • Lessons learned from a clinical trial. 
  • Lipid Testing and Statin Dosing After Acute Myocardial Infarction. 
  • Lipid-lowering Therapy in Patients With High Cardiovascular Risk: Dose or Combination? 
  • Lipoprotein (a): An Update on a Marker of Residual Risk and Associated Clinical Manifestations. 
  • Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. 
  • Long-term efficacy of repeated daily prefrontal transcranial magnetic stimulation (TMS) in treatment-resistant depression. 
  • Long-term histological effects of preemptive antiviral therapy in liver transplant recipients with hepatitis C virus infection. 
  • Low back pain. 
  • Maintenance of Weight Loss After Initiation of Nutrition Training: A Randomized Trial. 
  • Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. 
  • Major depressive disorder treatment guidelines in America and Europe. 
  • Management of Dyslipidemia for Cardiovascular Disease Risk Reduction: Synopsis of the 2020 Updated U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. 
  • Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement. 
  • Measurement of Low-Density Lipoprotein Cholesterol Levels in Primary and Secondary Prevention Patients: Insights From the PALM Registry. 
  • Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. 
  • Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. 
  • Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry. 
  • Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge: a randomized clinical trial. 
  • No survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. 
  • Opportunities for improving use of evidence-based therapy in patients with type 2 diabetes and cardiovascular disease. 
  • Oral Combination Therapies for Hepatitis C Virus Infection: Successes, Challenges, and Unmet Needs. 
  • Oral cleft prevention program (OCPP). 
  • Oral high-dose multivitamins and minerals after myocardial infarction: a randomized trial. 
  • Outcomes Among Older Patients Receiving Implantable Cardioverter-Defibrillators for Secondary Prevention: From the NCDR ICD Registry. 
  • Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. 
  • P2Y12 receptor inhibitors for secondary prevention of ischemic stroke. 
  • PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study. 
  • Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. 
  • Patient adherence to generic versus brand statin therapy after acute myocardial infarction: Insights from the Can Rapid Stratification of Unstable Angina Patients Suppress Adverse Outcomes with Early Implementation of the American College of Cardiology/American Heart Association Guidelines Registry. 
  • Patient-Centered Research into Outcomes Stroke Patients Prefer and Effectiveness Research: Implementing the patient-driven research paradigm to aid decision making in stroke care. 
  • Patient-Informed Treatment Development of Behavioral Smoking Cessation for People With Schizophrenia. 
  • Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. 
  • Personalized medicine and cancer supportive care: appropriate use of colony-stimulating factor support of chemotherapy. 
  • Pharmacologic treatment of acute and chronic stress following trauma: 2006. 
  • Pharmacotherapy of social anxiety disorder: what does the evidence tell us? 
  • Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. 
  • Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. 
  • Population-level incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA): Insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study. 
  • Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. 
  • Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. 
  • Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients. 
  • Predictive relationships between chronic pain and negative emotions: a 4-month daily process study using Therapeutic Interactive Voice Response (TIVR). 
  • Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry. 
  • Predictors of smoking relapse in patients with thoracic cancer or head and neck cancer. 
  • Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses. 
  • Public health clinical demonstration project for smoking cessation in american veterans who served since september 11, 2001. 
  • Pulmonary vein isolation for the maintenance of sinus rhythm in patients with atrial fibrillation: a meta-analysis of randomized, controlled trials. 
  • Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. 
  • RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. 
  • Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. 
  • Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. 
  • Randomized trial on mindfulness training for smokers targeted to a disadvantaged population. 
  • Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. 
  • Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. 
  • Rationale and design of the AngeLmed for Early Recognition and Treatment of STEMI trial: a randomized, prospective clinical investigation. 
  • Re: Early Physical Therapy for Acute Low Back Pain May Not Reduce Health Services Utilization, Costs, and Opioid Use. 
  • Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER. 
  • Regional variation in recommended treatments for ischemic stroke and TIA: Get with the Guidelines--Stroke 2003-2010. 
  • Reimplantation of a fluocinolone acetonide sustained drug delivery implant for chronic uveitis. 
  • Relapse following combined treatment discontinuation in a placebo-controlled trial for panic disorder. 
  • Relapse of depression after electroconvulsive therapy. 
  • Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. 
  • Religiosity as a protective factor in depressive disorder. 
  • Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? 
  • Reporting Clinical End Points and Safety Events in an Acute Coronary Syndrome Trial: Results With Integrated Collection. 
  • Representation of women in randomized clinical trials of cardiovascular disease prevention. 
  • Restenosis rates following vertebral artery origin stenting: does stent type make a difference? 
  • Return to play and physical performance tests: evidence-based, rough guess or charade? 
  • Rheumatic Heart Disease in the Twenty-First Century. 
  • Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. 
  • Risk factor profile and management of cerebrovascular patients in the REACH Registry. 
  • Risk factors associated with 90-day recurrent stroke in patients on dual antiplatelet therapy for minor stroke or high-risk TIA: a subgroup analysis of the CHANCE trial. 
  • Risks versus benefits of different types of long-acting injectable antipsychotics. 
  • Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis. 
  • Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. 
  • Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. 
  • Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. 
  • Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. 
  • Safety and efficacy outcomes of left atrial posterior wall isolation compared to pulmonary vein isolation and pulmonary vein isolation with linear ablation for the treatment of persistent atrial fibrillation. 
  • Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). 
  • Secondary prevention after coronary artery bypass graft surgery: findings of a national randomized controlled trial and sustained society-led incorporation into practice. 
  • Secondary prevention of ischaemic stroke: more evidence to block two pathways affecting platelet activation. 
  • Secondary prevention risk interventions via telemedicine and tailored patient education (SPRITE): a randomized trial to improve postmyocardial infarction management. 
  • Secondary prevention shifts into second gear. 
  • Secondary preventive medication persistence and adherence 1 year after stroke. 
  • Sildenafil: Possible Prophylaxis against Swimming-induced Pulmonary Edema. 
  • Similar secondary stroke prevention and medication persistence rates among rural and urban patients. 
  • Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. 
  • Statin Use and Adverse Effects Among Adults >75 Years of Age: Insights From the Patient and Provider Assessment of Lipid Management (PALM) Registry. 
  • Statins for Primary Prevention in Older Adults: An Unresolved Conundrum. 
  • Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial. 
  • Stress alleviation and reward enhancement: two promising targets for relapse prevention. 
  • Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. 
  • Survival After Secondary Prevention Implantable Cardioverter-Defibrillator Placement: An Analysis From the NCDR ICD Registry. 
  • System-integrated technology-enabled model of care to improve the health of stroke patients in rural China: protocol for SINEMA-a cluster-randomized controlled trial. 
  • Targeted interventions to prevent transitioning from acute to chronic low back pain in high-risk patients: development and delivery of a pragmatic training course of psychologically informed physical therapy for the TARGET trial. 
  • Temporal trends for secondary prevention measures among patients hospitalized with coronary artery disease. 
  • The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease. 
  • The Adherence eValuation After Ischemic Stroke Longitudinal (AVAIL) registry: design, rationale, and baseline patient characteristics. 
  • The Comprehensive Post-Acute Stroke Services (COMPASS) study: design and methods for a cluster-randomized pragmatic trial. 
  • The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. 
  • The comparison of epicardial focused ultrasound circumferential pulmonary vein ablation and BOX ablation--results from experimental acute atrial fibrillation. 
  • The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the Seychelles. 
  • The future of clinical trials in secondary prevention after acute coronary syndromes. 
  • The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. 
  • Therapeutic Interactive Voice Response for chronic pain reduction and relapse prevention. 
  • Therapy for ocular toxoplasmosis. 
  • Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry. 
  • Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. 
  • Time to relapse after 6 and 12 months' treatment of generalized anxiety disorder with venlafaxine extended release. 
  • Timing of First Postdischarge Follow-up and Medication Adherence After Acute Myocardial Infarction. 
  • Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Tobacco smoking and other suspected antecedents of nonmedical psychostimulant use in the United States, 1995. 
  • Toward individualized post-electroconvulsive therapy care: piloting the Symptom-Titrated, Algorithm-Based Longitudinal ECT (STABLE) intervention. 
  • Transcatheter closure of patent foramen ovale following cryptogenic stroke: An updated meta-analysis of randomized controlled trials. 
  • Transition of care for acute stroke and myocardial infarction patients: from hospitalization to rehabilitation, recovery, and secondary prevention. 
  • Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or Transient Ischemic Attack. 
  • Treatment Strategies for Deficiency of Adenosine Deaminase 2. 
  • Treatment of Recurrent Electrographic Nonconvulsive Seizures (TRENdS) study. 
  • Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (gusto I) and assessment of the safety of a new thrombolytic (assent 2) studies. 
  • Trends in outcomes among older patients with non-ST-segment elevation myocardial infarction. 
  • Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. 
  • Urinary Stone Disease: Advancing Knowledge, Patient Care, and Population Health. 
  • Use of Prescription Smoking Cessation Medications After Myocardial Infarction Among Older Patients in Community Practice. 
  • Use of beta-blockers in patients with an implantable cardioverter defibrillator. 
  • Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial. 
  • Using Telehealth to Disseminate Primary, Secondary, and Tertiary CVD Interventions to Rural Populations. 
  • Venous ulcer diagnosis, treatment, and prevention of recurrences. 
  • Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. 
  • Vorapaxar in the secondary prevention of atherothrombosis. 
  • Vorapaxar in the secondary prevention of atherothrombotic events. 
  • Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. 
  • Women's resources and use of strategies as risk and protective factors for reabuse over time. 
• 

  Keywords of People

  • Grambow, Steven C., Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics